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A B S T R A C T
Background. Variants of several genes encoding transcription modulators, signal transduction, and structural
proteins are known to cause Mendelian congenital heart disease (CHD). NKX2-5 and GATA4 were the ﬁrst
CHD-causing genes identiﬁed by linkage analysis in large affected families. Mutations of TBX5 cause Holt–Oram
syndrome, which includes CHD as a clinical feature. All three genes have a well-established role in cardiac
development.
Design. In order to investigate the possible role of multiple mutations in CHD, a combined mutation screening was
performed in NKX2-5, GATA4, and TBX5 in the same patient cohort. Samples from a cohort of 331 CHD patients
were analyzed by polymerase chain reaction, double high-performance liquid chromatography and sequencing in
order to identify changes in the NKX2-5, GATA4, and TBX5 genes.
Results. Two cases of multiple heterozygosity of putative disease-causing mutations were identiﬁed. One patient was
found with a novel L122P NKX2-5 mutation in combination with the private A1443D mutation of MYH6. A patient
heterozygote for a D425N GATA4 mutation carries also a private mutation of the MYH6 gene (V700M).
Conclusions. In addition to reporting two novel mutations of NKX2-5 in CHD, we describe families where multiple
individual mutations seem to have an additive effect over the pathogenesis of CHD. Our ﬁndings highlight the
usefulness of multiple gene mutational analysis of large CHD cohorts.
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Introduction
Congenital heart disease (CHD) is a complextrait, as both environmental and genetic
factors have been implicated in its pathogenesis.
The etiology of CHD has a strong genetic compo-
nent, as shown by extensive epidemiological studies
in large series of consecutive births.1,2 In approxi-
mately one in four cases, CHD occurs associated
with other congenital anomalies within a single-
gene disorder (e.g., Holt–Oram syndrome), spo-
radic malformative complex (e.g., VACTERL
association), or as a consequence of a chromosomal
abnormality (e.g., trisomy 21).3 Cases of isolated
CHD appear mainly as sporadic events. However,
a small fraction present as familial cases, often
showing Mendelian segregation with widely
variable penetrance.4 The ﬁrst genes involved in
Mendelian isolated CHD, NKX2-5 and GATA4,
which encode transcription factors, were identiﬁed
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by genetic linkage studies in large affected
families.5,6
The mammalian NKX2-5 gene was discovered
during a screening for mouse homologues of
tinman,7,8 a Drosophila gene essential for cardiac
development,9,10 the product of which has been
categorized as a Class I NK-2 homeodomain pro-
tein.11 This group of transcription factors bind to
the 5′-CAAGTG-3′ motif in target promoters.12
Murine NKX2-5 is expressed from day 7 in the
cardiac primordia8 and is an early marker of both
embryonic heart ﬁelds.13 Although mutations of
NKX2-5 are associated with a wide spectrum of
CHDs and thyroid dysgenesis,14 most manifest as
atrial septal defects (ASDs) and atrioventricular
block.15
The product of GATA4 belongs to the zinc-
ﬁnger family of transcription factors and, as the
other GATA proteins, it binds to the 5′-(A/C/
T)GATA(A/G)-3′ motif within its target
sequences.16 The mammalian GATA4 gene was
identiﬁed in a screen of zinc-ﬁnger encoding
cDNAs in a mouse library,17 and it was ﬁrst sus-
pected to be implicated in CHD when a deletion18
and a duplication19 of the chromosomal segment
in which it is contained were discovered in patients
with cardiac malformation. Most mutations of
GATA4 occur in the segments of the gene encod-
ing the zinc-ﬁnger motifs16 and have been related
to diverse types of CHDs.20
Mutations of TBX5 cause Holt–Oram syn-
drome, the most common of the heart–hand
syndromes.21,22 If strict criteria are used in Holt–
Oram syndrome diagnosis (i.e., at least one family
member with radial ray defect and cardiac septal
defects), mutation of TBX5 is found in more than
70% of cases.23 The vertebrate TBX5 gene was
discovered in a screen of mouse cDNA clones
using a probe complementary to the TBX2 T-box
region.24 It encodes a transcription factor and
alternative splicing regulator25 expressed in the
developing heart, among other tissues.21 Except
for somatic mutations,26 no variants of TBX5 have
been found to cause nonsyndromic CHD.
Physical and functional interaction to modulate
transcription of cardiac genes has been docu-
mented between the NKX2-5, GATA4, and TBX5
proteins.5,27,28 In order to evaluate the contribution
to multiple mutations in these genes in the patho-
genesis ofCHD,we conducted amutational scan of
the NKX2-5, GATA4, and TBX5 genes in a large
cohort of sporadic nonsyndromic CHD cases that
complements the ﬁndings of our previous analysis
ofMYH6 in the same cohort.29 We found two novel
mutations of the NKX2-5 gene and two instances
in which the distribution of changes in families is
consistent with additive effects of variants in differ-
ent genes in the pathogenesis of CHD.
Methods
Patients and Samples
The patient cohort comprised 331 patients with a
wide variety of CHDs. Peripheral blood samples
from all participants were taken after informed
consent and approval of the project by the local
ethics committees. Genomic DNA was puriﬁed
from blood using the QIAmp DNA blood Maxi kit
(Qiagen, Hilden, Germany) following the manu-
facturer directions. Anonymous human control
DNA panels were obtained from the European
Collection of Cell Culture (Salisbury, UK).
Denaturing High Performance Liquid
Chromatography (dHPLC)
Mutational analysis by dHPLC was performed as
described previously.30 Brieﬂy, to analyze the com-
bined 18 exons of the NKX2-5, GATA4, and TBX5
genes, 35 polymerase chain reaction (PCR) ampli-
conswere designed.Most of the amplicons spanned
individual exons and short segments of ﬂanking
introns to each side to detect mutations of splicing
regulatory elements. Large exons were spanned by
two overlapping amplicons. A pair of PCR primers
was designed for each amplicon (see Table 1). PCR
reactions were performed using patient and control
DNA samples following standard protocols. A ﬁnal
hybridization step for heteroduplex formation was
carried out heating the PCR products to 95°C and
cooling down 1.5°C perminute until a temperature
of 25°C was reached. Sequences of individual
amplicons were processed by the Navigator soft-
ware (Transgenomic, Omaha, NE, USA) in order
to plot themelting proﬁle of eachDNA segment to
determine the optimal dHPLC temperatures. PCR
products were analyzed on the dHPLC WAVE
System (Transgenomic). PCR products displaying
a trace indicative of heterozygosity were sequenced
by standard protocols. Novel potentially deleteri-
ous variants were screened by dHPLC in samples
from 384 ethnically matched control subjects.
Results
We identiﬁed two novel nonsynonymous muta-
tions in NKX2-5 compared with sequence acces-
sion number NM_004387.2 for the cDNA and
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NP_004378.1 for the protein. In exon 2, a
541T>C transition (L122P) was discovered in a
patient with secundum ASD (Figure 1A). The
mutation was transmitted by the unaffected father.
The same patient also harbors a private mutation
we reported previously (a 4395C>A transversion
resulting in A1443D) in exon 30 of the MYH6
gene, which was transmitted by the mother.29 A
Table 1. Summary of the Primers, Size, Annealing Temperature (Ta) of the Amplicons Used for the PCR Amplification of
the NKX2-5, GATA4, and TBX5 Genes and Temperatures Used in dHPLC
Amplicon Forward Primer Reverse Primer Size (bp) Ta dHPLC Temperatures
NKX2.5-E1P1 tgacacgaaactgctcatcg gtaggcctctggcttgaagg 416 56.6 63.3, 65.3, 67.3
NKX2.5-E1P2 ctggcgctgtgagactgg agtttcttggggacgaaagc 422 56 62, 63.6, 66.2, 67.4
NKX2.5-E2P1 caagccgctcttaccaagc cgttataaccgtagggattgagg 467 59.6 62.4, 65.6, 66.4
NKX2.5-E2P2 ccatgcctaggggactcg gggggacagctaagacacc 530 60.9 62.2, 63.9
NKX2.5-E2P3 attcactcctgcggagacc tcaatttgctcagggaatgc 461 54.1 59.3, 62.8, 64, 66.3
GATA4-E1 gtagcacttgggcattttcc ctacctccagacaagcaaagg 389 58.4 62.1, 64.3, 67.7
GATA4-E2P1 gtgggttctgaaagctctgg cctcggtgtcctctctctcc 497 58.4 57.4, 59.6, 62.3, 65.1
GATA4-E2P2 cacgcatattatcgttgttgc gccctggaggtaggacagg 267 54.7 64.3, 66.1, 68.8
GATA4-E2P3 cgtcctcgccagtctacg gtccccgggaaggagaag 586 60.9 66.2, 68.2, 68.8
GATA4-E3 aaagggcattgtttctgtgc agaggatgtcccaccaagg 344 54.1 58.6, 61.5, 64.1, 64.7
GATA4-E4 gagttaggtgccgtcacagg gagagatgggcatcagaagg 336 60.3 63.2, 65.1
GATA4-E5 caggtgtgtgtctttcaatgc tgattcttaggcactctgagg 229 57.7 58.5, 60.5
GATA4-E6 ccggctgttcgtttgtcc ctctgggactctgcagtcg 269 59.7 62.6, 65.1
GATA4-E7P1 cagcctagacctccaaagc acaggagagatgcagtgtgc 499 59.1 60.8, 61.4, 62.2
GATA4-E7P2 gacaatctggttaggggaagc ccagctgcattttgatgagg 470 58.4 59.4, 61.5, 63.3
GATA4-E7P3 gccctgcatccctaatacc cagcccttgggacactcc 482 59.8 58.2, 61.2
GATA4-E7P4 agtctggcaagcactcagc ccagtaggattttggagtgagg 484 59.4 61.2, 62.2
GATA4-E7P5 ctgcacattgctgtttctgc ctacacggcctcaagattcc 384 58.3 56.5, 58.1, 60.6
TBX5-E1P1 ggtattcatttgcccagagc cccagtaaaataaagaggcaacc 478 57.9 53.6, 59.2, 63.5, 64.9
TBX5-E1P2 ccagccaaacgtgacagc gccaagtgcaaagagaaacc 390 57.8 57.8, 60.4, 62.8
TBX5-E2 tttctctcgttctctctctgtcc cagactctgactttgatctctgc 297 60.2 62.8, 66.2
TBX5-E3 gtgttttgggggagtttgg gccaccttttcttcttcacc 243 57 58.9, 60.4
TBX5-E4 gaggctgccttaaaatactgg aactttttgggagaaggttcc 248 56.7 57.7, 60.2
TBX5-E5 ctggtgcgtgaactgaagc gaggacaagagggagacaagg 282 60.3 62.7, 65.1
TBX5-E6 gggagcagggttttatctgg tgcaaaagaaagagcagacg 280 54.3 54.6, 57.8, 61.1
TBX5-E7 tggcttaatttgcttcttttgg ggttgctgctggcttacc 294 53.4 56.5, 58.9
TBX5-E8 tctctcacacctggttcagc atactcctcaccccctcacc 390 60.3 58.7, 61.3
TBX5-E9P1 ttggccaaataactgtctcc gctggaacattccctctcc 465 54.1 56.3, 60.5, 63.8
TBX5-E9P2 acttctccgctcacttcacc tttttaaaattgtggtttcaagc 474 50.3 55.6, 59, 61.3, 63.5
TBX5-E9P3 ggacaagatttttcatttcacc ggtaggtgcttttcttagtcaagg 496 53.4 52.8, 56.4, 58, 59.3
TBX5-E9P4 ggacccagtcccttatttgg tttaatcagggagaatatttatttt 481 49.9 56.9, 58, 59.2
TBX5-E9P5 tggcctatagcttcccttcc ctcttggccagctcctatgc 482 60.3 53.1, 54.5, 56.7, 58.4
TBX5-E9P6 tgtgtaagtaaagtgttatggtagg aaagagacataatcgcataggg 361 56.9 52.1, 54.2, 57
TBX5-E9P7 aagagaacagggtaagatgtgagg ttcctgtttcctccaattcc 276 54.2 56.6, 58.7
PCR, polymerase chain reaction; dHPLC, denaturing high performance liquid chromatography.
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Figure 1. Sequence traces showing the nonsynonymous nucleotide changes causing amino acid replacements in the
NKX2.5, GATA4, and TBX5 proteins. The changes are indicated with arrows.
Congenit Heart Dis. 2012;7:151–159
Multiple Heterozygosity in CHD 153
870G>A (G232R) mutation (Figure 1B) was also
identiﬁed in exon 2 of a patient with pulmonary
valve stenosis that was transmitted by the appar-
ently unaffected mother. The G232R replaces an
uncharged glycine residue with a positively
charged arginine residue. Neither NKX2-5 muta-
tion was found in 384 ethnically matched control
subjects (768 chromosomes).
Three rare and one common nonsynonymous
variants ofGATA4were found in our CHD cohort.
They are identiﬁed according to their positions in
sequence accession number NM_002052.3
(cDNA) and NP_002043.2 (protein). A 1591C>T
transition (A346V) (Figure 1C) was discovered
within exon 6 in a patient with transposition of the
great arteries. A346V has been previously
described in a patient with endocardial cushion
defect.20 Also within exon 6, a transition 1692G>A
(V380M) was identiﬁed in a patient with a large
ventricular septal defect (VSD) (Figure 1D).
V380M has been reported as a pathogenic muta-
tion in CHD in one study,31 but another study
reports the same variant in 3 out of 318 control
subjects.32 V380M was not found in our control
cohort of 384 ethnically matched subjects. In exon
7, an 1827G>A (D425N) transition was found in
a patient with a large patent foramen ovale
(Figure 1E). The patient with this D425N muta-
tion has been reported recently,33 but no further
family data was published. The same mutation
has been reported previously in three CHD
patients.34,35The patient also carries a privatemuta-
tion in exon 18 of MYH6, a 2165G>A transition
(V700M).29 Two clinically normal sons are both
heterozygous for the GATA4 mutation but do not
carry the MYH6 mutation.
Analysis of the TBX5 gene revealed one syn-
onymous variant in our patient cohort. In exon
4, a transversion 998G>T (cDNA sequence
accession NM_000192.3) (Figure 1F) resulting
in D111Y (protein sequence accession
NP_000183.2) was discovered in a patient with
double outlet right ventricle, large ventricular
septal defect, large atrial septal defect, and patent
ductus arteriosus. We also found this variant in 3
out of 384 ethnically matched control samples.
Discussion
We have conducted a mutational scan of the
NKX2-5, GATA4, and TBX5 genes in a large
cohort of patients with a wide variety of CHDs.
We have identiﬁed two novel changes of NKX2-5
(L122P, G232R), one for TBX5 (D111Y), and
three previously known variants of GATA4
(A346V, V380M, and D425N).
The L122P change lies N-terminal to the
homeodomain of NKX2-5. An analysis of the
NKX2-5 wild-type and L122P mutant-derived
protein sequences using the nnpredict program36
indicates that the variant occurs within a segment
of the molecule that normally adopts an a-helical
secondary structure that is disrupted in the
mutant (Figure 2). This can be explained by the
observation that, when a proline residue is
located within an a-helical structure, the helix is
kinked by approximately 30 degrees to prevent a
steric clash between the pyrrolidine ring and the
preceding carbonyl oxygens.37 This suggests that
the private L122P mutation could affect the
function of the NKX2-5 protein by modifying
its three-dimensional conformation. This muta-
tion was inherited from the father. In the same
individual, there is another private mutation in a
different gene, MYH6, (A1443D) which was
transmitted by the mother (Figure 3A).29 Both
A B
Figure 2. nnpredict output showing the prediction of the structural consequence of the L122P mutation in NKX2.5. The
panels show the sequence of the wild-type (A) and mutant (B) NKX2.5 proteins. The relevant residues at position 122 are
underlined. The secondary structure prediction is shown for each sequence. The fourth helix predicted in the wild-type
sequence is 18 residues long (in bold). An eight-residue stretch within that segment is predicted to adopt a different
configuration in the mutant peptide (H, helix, E, strand, -. no prediction).
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parents are of white descent. The A1443D muta-
tion introduces a negatively charged residue in a
position where only noncharged amino acids
exist in sarcomeric myosins from mammals,
chick, zebraﬁsh, Xenopus, and Caenorhabditis
elegans and is predicted to interfere with the
interaction between the two molecules of the
myosin dimer or with other sarcomeric pro-
teins.29 The frequency of the alleles encoding
either L122P (NKX2-5) or A1443D (MYH6) in
the CHD and control cohorts is 0.000619. The
probability of both private alleles occurring in
the same individual by chance, assuming the vari-
ants do not have causal relation to the phenotype
is estimated to be 4.82 ¥ 10-7. The most common
phenotype resulting from mutations in either
NKX2-5 or MYH6 is secundum ASD.15,29,38 As
this patient has the same diagnosis, double het-
erozygocity could at least partially explain the
development of the defect in the proband and the
incomplete penetrance of the L122P and
A1443D mutations in the parents. Incomplete
penetrance is a common ﬁnding in documented
cases of mutations causing Mendelian CHD.4 In
the case of NKX2-5, recent data highlight the
profound inﬂuence of modiﬁer loci in the patho-
genesis of single-gene cardiac malformation.39
The novel NKX2-5 G232R mutation occurs in
the C-terminal end of the NK2-speciﬁc domain
(NK2-SD) and introduces a positively charged
residue in a position where only noncharged resi-
dues exist in every vertebrate NKX2-5 ortholog
sequence available (Figure 4A). The NK2-SD
interaction with bone morphogenetic protein
(BMP)-dependent mothers against decapentaple-
gic (SMAD) proteins is required for the binding of
the homeodomain with the histone deacetylase
(HDAC)/Sin3A complex.40 This domain is also
thought to stabilize the interaction of the tinman
domain to the corepressor Groucho proteins41 and
to modulate, in an intramolecular fashion, the
activity of the C-terminal activation domain.42
These data suggest that the G232R mutation
could compromise the transcriptional-repressor
activity of NKX2-5 and its responsiveness to BMP
signaling.
The novel D111Y TBX5 variant occurs within
the conserved T-box element of the molecule. A
three-dimensional structure model of the human
TBX5 protein (PDB: 2X6U) has been made avail-
able recently.43 This model allows more precise
predictions of the consequences of the variant
D111Y (Figure 5A). The structural model predicts
that the salt bridge present between the K126 and
D111 is disrupted when the aspartic acid residue
(D) is replaced, as in the case of the D111Y variant,
by an uncharged tyrosine (Y) residue (Figure 5B). A
model of the human TBX3 bound to its target
sequence (PDB: 1H6F)44 reveals that the side-
chains of both K126 and D111 point to opposite
directions during interaction with DNA, canceling
the salt bridge (Figure 5C) that suggests that the
D111Y variant could have an impact on the con-
formational change of TBX5 upon binding to its
target promoters. Both residues involved in the salt
bridge (D111 and K126) are universally conserved
in every TBX5 vertebrate sequence available
(Figure 4B).We suggest that these data warrant the
inclusion of the TBX5 D111Y variant in future
case-control studies for sporadic CHD, as this
variant could confer susceptibility to the disease.
The D425N mutation of GATA4 has been
reported previously in three patients with secun-
dum ASD, VSD, and tetralogy of Fallot.34,35 This
variation replaces a negatively charged aspartic
acid (D) residue for an uncharged asparagine (N)
residue in a position where only negatively
charged amino acids are found in GATA4
Figure 3. Pedigrees of the families CHD where multiple heterozygosity for the NKX2.5, GATA4, and MYH6 genes was
detected. ASD, atrial septal defect; PFO, patent foramen ovale.
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orthologs in wide range of vertebrate species
(Figure 4C). The patient heterozygous for D425N
also carries a private mutation in exon 18 of
MYH6, a 2165G>A transition (V700M)
(Figure 3B).29 This mutation is located within the
segment of the MYH6 gene encoding a part of the
SH1 helix that is conserved in every myosin
sequence available and is predicted to hinder the
movements of the helix at different stages of
the myosin cycle.29 Two clinically normal sons of
the proposita are both heterozygous for the
D425N GATA4 mutation but do not carry the
V700M MYH6 mutation. The patient suffered a
stillbirth but no sample from the product was
available for analysis. The structure of this pedi-
gree is consistent with complementation of both
variants to contribute to the phenotype
(Figure 3B).
A
B
C
Figure 4. Multiple alignment of amino acid sequences of segments of the NKX2-5, GATA4, and TBX5 proteins from every
vertebrate species available. (A) The NKX2-5 G232R mutation introduces a positively charged arginine residue in a position
where only noncharged amino acids are present in NKX2.5 vertebrate orthologs. (B) The TBX5 D111Y mutation replaces a
negatively charged aspartic acid residue with a noncharged tyrosine residue. Both amino acids forming a salt bridge
predicted by the human TBX5 tridimensional structure (PDB: 2X6U) are universally conserved among TBX5 vertebrate
orthologs. (C) The D425N GATA4 mutation introduces a noncharged residue in a position where only negatively charged
residues are present in every vertebrate GATA4 ortholog sequence available.
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Conclusions
Mendelian nonsyndromic CHD is known to be
caused by mutations of genes encoding transcrip-
tion factors4 and, notably, muscle proteins ex-
pressed in the developing heart or great vessels
like ACTC1,45 MYH6,29,38 MYH7,46 and
MYH11.47,48 Here, we describe two novel muta-
tions of NKX2-5 associated with CHD. Also, we
present cases where multiple heterozygosity of
variants could contribute, by additive effects, to
the development of individual cases of cardiac
malformation. Our ﬁndings highlight the useful-
ness of multiple gene analysis in large patient
CHD cohorts in order to identify variants whose
combined effects may cause the phenotype.
Although array-based genome-wide association
studies (GWAS) have been successful in identifying
chromosomal segments and variants associated
with complex phenotypes, in general, they only
explain a small fraction of their heritability.49
Recent ﬁndings suggest that a great proportion of
the “missing heritability” in GWAS studies can be
masked by incomplete linkage disequilibrium
between the causal variants and the single-
nucleotide polymorphisms (SNPs) typed by the
arrays, as causal variants would tend to have lower
minor allele frequencies than the typed SNPs.50
Thus, we suggest there is a need for further detailed
analysis of common, rare, and private variants of
genes implicated inMendelianCHD in association
studies aimed at identifying the genetic causes of
the more common, sporadic forms of the disease.
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